CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0152-000 |
|---|---|
| Brand Name | Tafinlar & Mekinist in combo |
| Generic Name | Dabrafenib & Trametinib in combo |
| Strength | 50 mg & 75 mg and 0.5 mg & 2.0 mg |
| Tumour Type | Skin & Melanoma |
| Indication | Melanoma Adjuvant Therapy |
| Funding Request | For the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | September 21, 2018 |
| Manufacturer | Novartis Pharmaceuticals Canada Inc. |
| Sponsor | Novartis Pharmaceuticals Canada Inc. |
| Submission Date | September 21, 2018 |
| Submission Deemed Complete | October 5, 2018 |
| Submission Type | Initial |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 5, 2018 |
| Check-point meeting | November 14, 2018 |
| pERC Meeting | February 21, 2019 |
| Initial Recommendation Issued | March 7, 2019 |
| Feedback Deadline ‡ | March 21, 2019 |
| pERC Reconsideration Meeting | April 18, 2019 |
| Final Recommendation Issued | May 3, 2019 |
| Notification to Implement Issued | May 21, 2019 |
| Therapeutic Area | Melanoma Adjuvant Therapy |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
